Obeticholic acid and ferrostatin-1 differentially ameliorate non-alcoholic steatohepatitis in AMLN diet-fed ob/ob mice
Introduction: Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are common chronic liver diseases with limited treatment options.Methods: Ob/ob mice (6 weeks old) were fed with the Control diet or amylin liver NASH (AMLN) diet for 24 weeks to establish the NASH, the...
Main Authors: | Shengjie Li, Aoxiang Zhuge, Kaicen Wang, Jiafeng Xia, Qiangqiang Wang, Shengyi Han, Jian Shen, Lanjuan Li |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-12-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.1081553/full |
Similar Items
-
Microbiota-induced lipid peroxidation impairs obeticholic acid-mediated antifibrotic effect towards nonalcoholic steatohepatitis in mice
by: Aoxiang Zhuge, et al.
Published: (2023-02-01) -
Ferrostatin-1 inhibits fibroblast fibrosis in keloid by inhibiting ferroptosis
by: Liu Yang, et al.
Published: (2024-06-01) -
Bioequivalence and Pharmacokinetic Profiles of Generic and Branded Obeticholic Acid in Healthy Chinese Subjects Under Fasting and Fed Conditions
by: Wang MN, et al.
Published: (2021-01-01) -
Obeticholic Acid: A New Era in the Treatment of Nonalcoholic Fatty Liver Disease
by: Ludovico Abenavoli, et al.
Published: (2018-10-01) -
Ferrostatin-1 alleviates lipopolysaccharide-induced acute lung injury via inhibiting ferroptosis
by: Pengfei Liu, et al.
Published: (2020-02-01)